Journal of Medicinal Chemistry p. 3826 - 3839 (2016)
Update date:2022-08-15
Topics:
Zhao, Fei
Li, Jing
Chen, Ying
Tian, Yanxin
Wu, Chenglin
Xie, Yanan
Zhou, Yu
Wang, Jiang
Xie, Xin
Liu, Hong
A series of indoline and indole derivatives were designed, synthesized, and evaluated as selective α1A-adrenergic receptor (α1A-AR) antagonists for the treatment of benign prostatic hyperplasia (BPH). In this study, two highly selective and potent α1A-AR antagonists, compounds (R)-14r (IC50 = 2.7 nM, α1B/α1A = 640.1, α1D/α1A = 408.2) and (R)-23l (IC50 = 1.9 nM, α1B/α1A = 1506, α1D/α1A = 249.6), which exhibited similar activities and better selectivities in cell-based calcium assays as compared with the marketed drug silodosin (IC50 = 1.9 nM, α1B/α1A = 285.9, α1D/α1A = 14.4), were identified. In the functional assays with isolated rat tissues, compounds (R)-14r and (R)-23l also showed high potency and uroselectivity. Most importantly, (R)-14r and (R)-23l can significantly decrease the micturition frequency and increase the mean voided volume of the BPH rats in a dose-dependent manner, making them worthy of further investigation for the development of anti-BPH agents.
View MoreShiJiaZhuang Dowell Chemical Co.,Ltd.
website:http://www.dowechem.com
Contact:+86-13463963265,+86-311-89805679
Address:Xiyangling village, high tech Zone, Shijiazhuang,Hebei, China
Shijiazhuang Haitian Amino Acid Co., Ltd.
Contact:+86-311-88908111
Address:Shijiazhuang Hebei province,China
ABA Chemicals (Shanghai) Limited
Contact:021- 5115 9199-232
Address:Suite 18D, #201 Ningxia Road,
Shouguang Nuomeng Chemical Co., Ltd.
Contact:+86-536-5119508/18363669993
Address:Hou Zhen Industrial Park, Shouguang, Shandong, China
Contact:86-574-83851061 86-574-87083208
Address:Room 905, No.3 Building,East Business Center, 456 Xingning Road, Ningbo City,China
Doi:10.1002/(SICI)1099-1344(199603)38:3<255::AID-JLCR835>3.0.CO;2-0
(1996)Doi:10.1021/ja954021i
(1996)Doi:10.1055/s-0037-1611354
(2019)Doi:10.1002/anie.201411518
(2015)Doi:10.1016/0040-4039(95)00206-R
(1995)Doi:10.3762/bjoc.14.35
(2018)